Landmark Bio

Landmark Bio is a specialized CDMO focused exclusively on the cell and gene therapy sector, established as a unique cross-sector partnership between academia and industry. Founded with academic partners Harvard and MIT and industrial partners Cytiva and FUJIFILM Diosynth Biotechnologies, it aims to accelerate the translation of groundbreaking research into clinical therapies. The company offers a full suite of services from technology development and IND-enabling studies to clinical manufacturing, targeting both academic researchers and biopharma companies. Its core philosophy emphasizes transparency, collaboration, and flexible partnership models to de-risk and accelerate client programs.

Integrated CDMO services leveraging academic partnerships (Harvard, MIT) for early-stage technology development and industrial partnerships (Cytiva, FUJIFILM Diosynth) for scalable process and manufacturing expertise in cell and gene therapies.

Landmark Bio competes in the advanced therapy CDMO space against large global players like Lonza, Catalent, and Thermo Fisher, as well as specialized peers. Its differentiation lies in its formal academic partnerships and focused translational model, targeting the early-stage, high-complexity segment of the market.